在血管样条纹继发的脉络膜新生血管中从雷珠单抗转换为阿柏西普。
Switching from ranibizumab to aflibercept in choroidal neovascularization secondary to angioid streaks.
作者信息
Sekfali Rim, Mimoun Gérard, Cohen Salomon Yves, Querques Giuseppe, Bandello Francesco, Sacconi Riccardo, Souied Eric H, Capuano Vittorio
机构信息
Department of Ophthalmology, Centre Hospitalier Intercommunal de Créteil, University Paris-Est Créteil, Créteil, France.
Centre Ophtalmologique d'Imagerie de l'Ecole Militaire, Paris, France.
出版信息
Eur J Ophthalmol. 2020 May;30(3):550-556. doi: 10.1177/1120672119838133. Epub 2019 Mar 18.
PURPOSE
To evaluate the efficacy of switching from intravitreal ranibizumab to intravitreal aflibercept in choroidal neovascularization secondary to angioid streaks.
DESIGN
Multicenter retrospective interventional case series.
METHODS
Patients previously treated with intravitreal ranibizumab with at least 12-month follow-up (M12) after switching (M0) to intravitreal aflibercept. Switch to intravitreal aflibercept was decided in cases of or choroidal neovascularization. Primary endpoint: Change of best-corrected visual acuity using the Early Treatment Diabetic Retinopathy Study letters. Secondary endpoints: Mean change of central macular thickness, absence of intraretinal/subretinal fluid on spectral domain optical coherence tomography and the percentage of eyes with absence of leakage on fluorescein angiography.
RESULTS
Fourteen eyes of 13 patients were included. Mean best-corrected visual acuity was 65.0 ± 21.03 letters at M0 and 63.5 ± 17.30 letters at M12 (p = 0.5). Secondary endpoints: Mean central macular thickness was 344 ± 194.65 µm at M0 and 268 ± 79.97 µm at M12 (p = 0.008). Absence of intraretinal/subretinal fluid was observed in 71%. Fluorescein angiography (nine eyes) showed absence of leakage in 77% (seven eyes).
CONCLUSION
Switching from intravitreal ranibizumab to intravitreal aflibercept represents a therapeutic option in patients with or choroidal neovascularization secondary to angioid streaks.
目的
评估玻璃体内注射雷珠单抗转换为玻璃体内注射阿柏西普治疗血管样条纹继发脉络膜新生血管的疗效。
设计
多中心回顾性介入病例系列研究。
方法
患者先前接受玻璃体内注射雷珠单抗治疗，转换（M0）为玻璃体内注射阿柏西普后至少随访12个月（M12）。在出现[具体情况未明确，原文此处缺失]或[具体情况未明确，原文此处缺失]脉络膜新生血管的病例中决定转换为玻璃体内注射阿柏西普。主要终点：使用早期糖尿病性视网膜病变研究视力表测定的最佳矫正视力变化。次要终点：中心黄斑厚度平均变化、频域光学相干断层扫描显示视网膜内/视网膜下无液以及荧光素血管造影显示无渗漏的眼的百分比。
结果
纳入13例患者的14只眼。M0时平均最佳矫正视力为65.0±21.03个字母，M12时为63.5±17.30个字母（p = 0.5）。次要终点：M0时中心黄斑厚度平均为344±194.65μm，M12时为268±79.97μm（p = 0.008）。71%的患者视网膜内/视网膜下无液。荧光素血管造影（9只眼）显示77%（7只眼）无渗漏。
结论
对于血管样条纹继发[具体情况未明确，原文此处缺失]或[具体情况未明确，原文此处缺失]脉络膜新生血管的患者，从玻璃体内注射雷珠单抗转换为玻璃体内注射阿柏西普是一种治疗选择。
Zotero 插件